ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2747

Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival

Stig Tengesdal and Geirmund Myklebust, Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis, methotrexate (MTX) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy is poorly investigated. The aim of this study was to compare efficacy, safety and drug survival between MTX and LEF in the treatment of GCA.

Methods: During 2007-2017 all patients diagnosed with GCA at the Department of Rheumatology were included in a hospital-based retrospective study. All patients receiving MTX and/or LEF due to insufficiency and/or adverse effects of treatment with Prednisolone were identified. Duration of treatment, causes of discontinuation and changes in Prednisolone dose, Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were registered. Concomitant myalgia and/or polymyalgia rheumatica (PMR) and large vessel involvement (LVI) (involvement of aorta and its primary and secondary branches) were noted. Remission was defined as doctor’s opinion of clinical remission and a Prednisolone dose ≤5mg/day. Baseline Prednisolone dose and CRP values were unevenly distributed between the groups. Therefore the effect in patients with a Prednisolone dose >7.5 mg at start of treatment were analyzed separately, interpreted as a group of patients with higher disease activity. Student-t test was used to compare means and Chi-square test to compare categorical variables. All statistical analyses were performed using the SPSS statistical package version 23.

Results: 216 patients (70.4% women) were included (mean age 72.9 at time of diagnosis). Twenty-seven and 24 patients started treatment with LEF and MTX, respectively. During the treatment-period, the observed mean reduction in Prednisolone dose, ESR and CRP did not differ significantly. No significant difference between LEF and MTX in treatment duration to achieve remission/still on treatment was found (p=0.19). For patients with higher disease activity (Prednisolone >7.5mg), this difference was significant favoring LEF (p=0.02). In the same group, a non-significant difference was found in the time to discontinuation due to adverse effects (p=0.13). There were no differences in the number of adverse effects in the treatment groups, most of them mild and well known.

Conclusion: To our knowledge this is the first study to compare LEF and MTX in the treatment of GCA. Patients treated with LEF achieved remission earlier than MTX, and this difference was significant in patients with higher disease activity (p=0.02). We found no difference in tolerability and reduction in ESR and CRP after 6 months of treatment between the groups.


Disclosure: S. Tengesdal, None; G. Myklebust, None.

To cite this abstract in AMA style:

Tengesdal S, Myklebust G. Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/leflunomide-and-methotrexate-in-treatment-of-giant-cell-arteritis-comparison-of-efficacy-safety-and-drug-survival/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leflunomide-and-methotrexate-in-treatment-of-giant-cell-arteritis-comparison-of-efficacy-safety-and-drug-survival/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology